Overview

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Status:
Terminated

Trial end date:
2018-10-26

Target enrollment:

Participant gender:

Summary

To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumors and in combination with durvalumab in subjects with solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

MedImmune LLC

Treatments:

Durvalumab
MEDI9197